Nuvalent, Inc.

NASDAQ:NUVL

Biotechnology

Healthcare
$123.96 -0.02%

-$0.03 today

Market cap
$9.13B
Beta
1.15
P/E (TTM)
-21.6
EPS (TTM)
-$5.72
52W Low $71.13High $123.62

Volume 0.00M

Average 1.91M

NUVL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nuvalent, Inc.NASDAQ: NUVL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $83.61M rose 12.3% year over year, behind the +24.7% change in trailing-twelve-month research & development. Sequentially, it rose 23.3% from the prior quarter. Over 3 fiscal years it compounded at +68.9% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.3% toward the trailing-twelve-month pace of +24.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$83.61M+23.3% QoQ
Last fiscal yearDec 2025
$306.97M+41.0% YoY
LTMMar 2026
$316.16M+24.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%——
1 year+41.0%——
3-year CAGR+68.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
306.97M USD
Year-over-year change
+41.0%
4-year CAGR
+71.4%

Research & Development vs competitors

How NUVL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.7% is the 2nd highest of 9, against a peer median of +4.8%.
  • Over three fiscal years its annual growth of +68.9% compares with a peer median of +24.1%.
NUVL Competitors
Research & Development for NUVL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$739.14M USD+21.7%+29.3%164.0%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$623.61M USD-26.8%+9.9%13.2%
CYTKCytokinetics, IncorporatedLTM Jun 2026$394.1M USD+0.9%+19.0%555.4%
NUVLNuvalent, Inc.LTM Mar 2026$316.16M USD+24.7%+68.9%—
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M USD+1.6%-16.9%1125.4%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M USD-3.5%+46.8%24.2%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$179.67M USD+7.9%+15.5%64.0%
ABVXAbivax S.A.FY2025€177.76M EUR+21.3%+54.4%—
Peer median (excluding NUVL) —+4.8%+24.1%114.0%

Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.56M63.73M113.24M217.77M306.97M
Selling, General & Admin10.26M22.38M36.25M62.59M107.34M
Operating Expenses45.82M86.11M149.49M280.37M414.31M
Depreciation & Amortization215K00280.37M414.31M
EBITDA(46.12M)(81.85M)(126.22M)20.38M(10.49M)
EBITDA Margin—————
Operating Income(45.82M)(86.11M)(149.49M)(280.37M)(414.31M)
Operating Margin—————
Interest Income0023.27M38.32M44.74M
Interest Expense0023.27M00
Other Income / Expenses(521K)4.25M23.27M20.38M(10.49M)
Income Before Tax(46.34M)(81.85M)(126.22M)(259.99M)(424.79M)
Pre-Tax Margin—————
Income Tax Expense000764K585K
Net Income(46.34M)(81.85M)(126.22M)(260.76M)(425.38M)
Net Margin—————
EPS (Basic)(2.13)(1.65)(2.17)(3.93)(5.85)
EPS (Diluted)(2.13)(1.65)(2.17)(3.93)(5.85)
Weighted Avg Shares21.78M49.67M58.22M66.41M72.69M
Weighted Avg Shares (Diluted)21.78M49.67M58.22M66.41M72.69M

Nuvalent, Inc.

NASDAQ:NUVL

Intrinsic Alpha fair value

Locked

Current Price

$123.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.